Bharat in BetaAffordable cell and gene therapy production platforms
Source
- Speciale Invest, India's Biotech Inflection Point (opens in a new tab)Moat TwoPublished: 4 Mar 2026
The idea
Develop locally integrated manufacturing and clinical capabilities to broaden access.
Why this is interesting
- The article treats lower-cost development and manufacturing of cell and gene therapies in India as an advantage. Cost helps only if quality, clinical evidence and supply reliability hold up, and those are the hardest parts to build.
- Speciale Invest presents this as one of India’s advantages from a pre-seed investor’s perspective. That is a thesis about where defensibility may come from, not a named buyer or a demand signal.
Possible starting points
Local supply of production inputs
Identify reagents or consumables for cell therapy production that are imported and could be supplied locally at the required quality.
Hospital delivery capability
Support hospitals with the steps around an advanced therapy, such as cell collection logistics and patient follow-up.
Questions to answer
- Which cost component dominates for the target therapy, and can a startup change it?
- What evidence would a regulator and a treating hospital require?